Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company has put the launch on ice while it waits for the coronavirus pandemic to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results